ProQR Therapeutics N.V.
About ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $158.0M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $158.0M
- Shares outstanding
- 112.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 18, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 54% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ProQR Therapeutics N.V..
Write a review
News about ProQR Therapeutics N.V.
News & sentiment via Polygon.io
